International journal of clinical practice
-
Int. J. Clin. Pract. · Feb 2021
Long-term outcomes of minimally invasive surgeries in partial nephrectomy. Robot or laparoscopy?
To compare long-term oncological and renal functional outcomes of laparoscopic and robotic partial nephrectomy for small renal masses. ⋯ In this study, perioperative and long-term oncological and functional outcomes seems to be comparable between laparoscopic and robotic partial nephrectomies.
-
Int. J. Clin. Pract. · Feb 2021
Retroperitoneal robot-assisted laparoscopic partial nephrectomy for posterior located renal tumors: technique and early-term outcomes.
Traditionally, the trans-peritoneal approach is preferred for robot-assisted partial nephrectomy (RPN). However, retroperitoneal RPN (RP-RPN) has recently become widespread because of the advantages of easier access to the hilum, ease dissection of posterior tumours, and lower probability of intra-peritoneal organ injury. We aimed to present our initial experience of the RP-RPN series in posteriorly located renal tumours. ⋯ RP-RPN is a safe and feasible approach with acceptable oncological and functional results. We think that RP-RPN can be applied as an alternative to the trans-peritoneal approach for selected cases, especially in renal tumours with the posterior location.
-
Int. J. Clin. Pract. · Feb 2021
Real-time ultrasound-guided internal jugular vein cannulation by oblique-axis in-plane: Practice at the Fourth Hospital of Hebei Medical University.
We aimed to evaluate oblique-axis in-plane (OA-IP) techniques for real-time ultrasound-guided internal jugular vein (IJV) cannulation. ⋯ The results of our study suggest that OA-IP techniques can improve ultrasound-guided IJV cannulation with a high success rate and safety in clinical practice. Clinicians should consider adopting these methods.
-
Int. J. Clin. Pract. · Feb 2021
ReviewSwitching between GLP-1 receptor agonists in clinical practice: expert consensus and practical guidance.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are an established treatment for patients with type 2 diabetes (T2D). Differences between GLP-1RAs in pharmacokinetics, dosing regimens and clinical effects, including cardiovascular (CV) outcomes, mean there may be benefits to switching from one to another. However, clinical guidance on switching is lacking and data from clinical trials are limited. This article provides a clinical perspective and consensus on the benefits of switching between GLP-1RAs, the triggers for switching and how best to manage this in clinical practice. Once weekly (OW) semaglutide is used as an example to illustrate how the authors might switch to a different GLP-1RA in clinical practice. ⋯ Switching from one GLP-1RA to another, such as OW semaglutide, can provide clinical benefits and may delay the need for treatment intensification.
-
Int. J. Clin. Pract. · Feb 2021
Observational StudyDevelopment and validation of a Score to Assess Risk of Medication Errors detected during medication reconciliation process at admission in Internal Medicine Unit: SCOREM study.
Medication errors (ME) can be reduced through preventive strategies such as medication reconciliation. Such strategies are often limited by human resources and need targeting high risk patients. ⋯ Risk factors identified in our study may help prioritising patients admitted in internal medicine units who may benefit the most from medication reconciliation (ClinicalTrials.gov number NCT03422484).